Our Final Take Obviously, Biogen is in the business of making money. It would not have offered to buy Sage at $7.22 a share if it did not believe it would be attractive to Biogen's shareholders.

On Friday evening, Sage said that Biogen had offered to buy the roughly 90% of Sage it does not already own for $469 million, or $7.22 a share.

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...

Sage Therapeutics, Inc. (SAGE) recently received an unsolicited bid proposal from Biogen Inc. (BIIB) to be purchased at around $7.22 per share. This represents a 30% premium to the price of the ...

Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral inves ...

BIIB's Recent Offer to Acquire SAGE Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share.

The collaboration between Biogen and Sage dates to 2020. Biogen committed $1.5 billion up front to begin the R&D alliance focused on depression and movement disorders. Results have been disappointing.

TipRanks Jan. 13, 2025, 08:40 AM BMO Capital says Biogen (BIIB) is looking for an early potential deal by offering to buy Sage Therapeutics (SAGE) for $7.22 per share.

Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by ...

Sage and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct further clinical development. The companies are evaluating next steps, if any, for other ...

Shares of Sage Therapeutics Inc. fell more than 18% premarket on Wednesday after a failed trial dealt a blow to the company’s collaboration with Biogen Inc.

Sage Therapeutics, Inc. and Biogen Inc. announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 as a potential treatment in essential tremor ...